While the majority of research to date has focused on more traditional risk factors associated with the development of MetS, recent investigations have led to identification of abnormal peptide profile of ghrelin gene products, growth hormone (GH), and insulin in individuals with MetS (Mora et al., 2014, 2015). This evidence concerns the gene GH1 and metabolic syndrome.